Linden; Joel M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Linden; Joel M..The latest application filed is for "2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity".

Company Profile

0.28.26

Linden; Joel M. - Charlottesville VA
Linden; Joel M. - La Jolla CA
Linden, Joel M - Charlottseville VA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease Grant 8,193,200 - Sitaraman , et al. June 5, 2	2012-06-05
Use of adenosine A.sub.2A modulators to treat spinal cord injury Grant 8,188,063 - Li , et al. May 29, 2	2012-05-29
Method to treat sickle cell disease Grant 8,178,509 - Linden , et al. May 15, 2	2012-05-15
2-propynyl adenosine analogs having A2A agonist activity and compositions thereof Grant 8,158,604 - Linden , et al. April 17, 2	2012-04-17
Method of treating ischemia reperfusion injury by inhibiting NKT cell activity Grant 8,012,484 - Linden , et al. September 6, 2	2011-09-06
2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity Grant 7,989,431 - Rieger , et al. August 2, 2	2011-08-02
2-propynyl Adenosine Analogs With Modified 5'-ribose Groups Having A2a Agonist Activity App 20110136755 - Rieger; Jayson M. ; et al.	2011-06-09
2-polycyclic propynyl adenosine analogs having A2A agonist activity Grant 7,875,595 - Rieger , et al. January 25, 2	2011-01-25
2-propynyl Adenosine Analogs Having A2a Agonist Activity And Compositions Thereof App 20100152127 - Linden; Joel M. ; et al.	2010-06-17
2-propynyl adenosine analogs having A2A agonist activity and compositions thereof Grant 7,737,127 - Linden , et al. June 15, 2	2010-06-15
2-polycyclic Propynyl Adenosine Analogs Having A2a Agonist Activity App 20090298788 - Rieger; Jayson M. ; et al.	2009-12-03
2-propynyl adenosine analogs with modified 5'-ribose groups having A.sub.2A agonist activity Grant 7,605,143 - Rieger , et al. October 20, 2	2009-10-20
2-polycyclic propynyl adenosine analogs having A2A agonist activity Grant 7,576,069 - Rieger , et al. August 18, 2	2009-08-18
Adjunctive Treatment Of Biological Diseases App 20090170803 - Linden; Joel M. ; et al.	2009-07-02
Method Of Treating Enteritis, Intestinal Damage, And Diarrhea From C. Difficile With An A2a Adenosine Receptor Agonist App 20080312160 - Guerrant; Richard L. ; et al.	2008-12-18
2-polycyclic propynyl adenosine analogs having A2A agonist activity Grant 7,442,687 - Rieger , et al. October 28, 2	2008-10-28
Method Of Treating Ischemia Reperfusion Injury By Inhibing Nkt Cell Activity App 20080254037 - Linden; Joel M. ; et al.	2008-10-16
Method to reduce inflammatory response in transplanted tissue Grant 7,427,606 - Linden , et al. September 23, 2	2008-09-23
Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease App 20080176845 - Sitaraman; Shanthi V. ; et al.	2008-07-24
Agonists of A2A adenosine receptors for treatment of diabetic nephropathy Grant 7,396,825 - Okusa , et al. July 8, 2	2008-07-08
Method to reduce an inflammatory response from arthritis Grant 7,378,400 - Rieger , et al. May 27, 2	2008-05-27
Use Of Adenosine A2a Modulators To Treat Spinal Cord Injury App 20080064653 - Li; Yuesheng Jason ; et al.	2008-03-13
Method To Treat Gastric Lesions App 20080027022 - Linden; Joel M. ; et al.	2008-01-31
Method To Treat Sickle Cell Disease App 20080009460 - Linden; Joel M. ; et al.	2008-01-10
Methods And Compositions For Treating Inflammatory Response App 20070265440 - Linden; Joel M. ; et al.	2007-11-15
2-propynyl Adenosine Analogs Having A2a Agonist Activity And Compositions Thereof App 20070232559 - Linden; Joel M. ; et al.	2007-10-04
Pharmaceutical compositions having A.sub.2A adenosine receptor agonist activity Grant 7,226,913 - Linden , et al. June 5, 2	2007-06-05
2-propynyl adenosine analogs having A.sub.2A agonist activity and compositions thereof Grant 7,214,665 - Linden , et al. May 8, 2	2007-05-08
Method Of Targeting A2b Adenosine Receptor Antagonist Therapy App 20070059740 - Linden; Joel M.	2007-03-15
2-Polycyclic propynyl adenosine analogs having A2A agonist activity App 20060217343 - Rieger; Jayson M. ; et al.	2006-09-28
Method to reduce an inflammatory response from arthritis App 20060100169 - Rieger; Jayson M. ; et al.	2006-05-11
2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors Grant 7,019,027 - Linden , et al. March 28, 2	2006-03-28
2-propynyl adenosine analogs with modifed 5'-ribose groups having A2A agonist activity App 20060040888 - Rieger; Jayson M. ; et al.	2006-02-23
2-polycyclic propynyl adenosine analogs having A2A agonist activity App 20060040889 - Rieger; Jayson M. ; et al.	2006-02-23
Agonists of A2A adenosine receptors for treatment of diabetic nephropathy App 20050261236 - Okusa, Mark D. ; et al.	2005-11-24
Method to reduce inflammatory response in transplanted tissue App 20050182018 - Linden, Joel M. ; et al.	2005-08-18
2-Amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors App 20040180948 - Linden, Joel M. ; et al.	2004-09-16
2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors Grant 6,713,638 - Linden , et al. March 30, 2	2004-03-30
Method and compositions for treating the inflammatory response Grant 6,670,334 - Linden , et al. December 30, 2	2003-12-30
2-propynyl adenosine analogs having A2A agonist activity and compositions thereof App 20030186926 - Linden, Joel M. ; et al.	2003-10-02
Methods and compositions for treating inflammatory response App 20030162742 - Linden, Joel M. ; et al.	2003-08-28
2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors App 20030078248 - Linden, Joel M. ; et al.	2003-04-24
Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors Grant 6,545,002 - Linden , et al. April 8, 2	2003-04-08
Methods and compositions for treating inflammatory response Grant 6,531,457 - Linden , et al. March 11, 2	2003-03-11
Method compositions for treating the inflammatory response Grant 6,514,949 - Linden , et al. February 4, 2	2003-02-04
Method for treating restenosis with A2A adenosine receptor agonists Grant 6,448,235 - Linden , et al. September 10, 2	2002-09-10
Method and compositions for treating the inflammatory response App 20020111327 - Linden, Joel M. ; et al.	2002-08-15
Method For Treating Restenosis With A2a Adenosine Receptor Agonists App 20020082240 - Linden, Joel M ; et al.	2002-06-27
Induction of pharmacological stress with adenosine receptor agonists Grant 6,322,771 - Linden , et al. November 27, 2	2001-11-27
Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors Grant 6,303,619 - Linden October 16, 2	2001-10-16
Methods and compositions for treating inflammatory response App 20010027185 - Linden, Joel M. ; et al.	2001-10-04
8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors Grant 6,117,878 - Linden September 12, 2	2000-09-12
Method for improving insulin sensitivity using an adenosine receptor antagonist Grant 6,060,481 - LaNoue , et al. May 9, 2	2000-05-09
Method for treating inflammatory diseases with A.sub.2a adenosine receptor agonists Grant 5,877,180 - Linden , et al. March 2, 1	1999-03-02

Company Registrations

NCAGE Code	49XP3	LINDEN JOEL M
CAGE Code	49XP3	LINDEN, JOEL M
DUNS	617633800	LINDEN, JOEL M

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.